GenesisCare continues to expand Spanishcancer services with Elekta
STOCKHOLM, October 25, 2016 – Elekta (EKTA-B.ST) announces that GenesisCare will acquire Versa HD™ linear accelerators to help fulfil its ambition to improve cancer care for patients in Spain. The deal also includes Elekta’s MOSAIQ® oncology information system to optimize the clinical care and operational efficiency of GenesisCare in Spain.
Francois Pointurier, Elekta’s Senior Vice President Region EMEA, says: “Although we have seen an increase in the incidence of cancer in Spain, the number of cancer deaths has fallen, thanks in part to improved treatment using advanced radiation therapy devices. We are proud to continue to partner with GenesisCare as they expand in Spain and grow in the European market. GenesisCare will receive the most advanced and recognized cancer treatment solutions on the market. We look forward to providing the platforms to support GenesisCare’s vision to provide accurate, efficient and high quality treatment.”
Following the recent acquisition of oncology groups, IMOncology and Oncosur, GenesisCare is now the largest cancer care provider in Spain.
Dan Collins, Managing Director at GenesisCare, says: “By investing in the latest technology and staff training we are providing our patients with access to more efficient and effective care. This will enable our physicians and staff to offer a smoother patient experience and improve patient outcomes. The suite of advanced technology solutions, global influence and commitment to innovation offered by Elekta will support our shared efforts to improve cancer services across Spain.”
Versa HD is Elekta’s most advanced linear accelerator, used to accurately and quickly deliver radiation therapy. MOSAIQ is a comprehensive oncology information system that centralizes traditional radiation oncology, particle therapy and medical oncology patient data into a single user interface, accessible by multidisciplinary teams across multiple locations.
The total order is valued at EUR 25 million, of which approximately EUR 9.5 million was booked in the second quarter of Elekta’s fiscal year. This agreement is in addition to an earlier deal with GenesisCare announced on March 31, 2016.
# # #
For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: firstname.lastname@example.org
Time zone: CET: Central European Time
Tobias Bülow, Director Financial Communication, Elekta AB
Tel: +46 722 215 017, e-mail: email@example.com
Time zone: CET: Central European Time
This information is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 07:30 CET on October 25, 2016.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,600 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: www.elekta.com.
GenesisCare provides high quality specialist care to patients with cancer and cardiovascular disease, the two largest disease burdens globally.
The organisation exists to improve quality and access for patients and communities in need. The group is the largest provider of radiotherapy across Australia, operating 27 cancer centres in major metropolitan and also regional settings (including in tertiary teaching public hospitals). 80 locations provide cardiology or sleep services. GenesisCare employs over 1700 highly trained health professionals and support staff including more than 150 physicians and leads, or participates, in approximately 100 clinical trials.
Cancer care is provided for all tumor groups with the latest techniques including intensity modulated radiotherapy, volumetric arc therapy, stereotactic radiotherapy and radiosurgery, low dose rate and high dose rate brachytherapy.
The GenesisCare medical team is comprised of some of the world’s most experienced specialists with many dedicating time as consultants in public hospitals or participating in research and teaching. GenesisCare adopts internationally proven medical technologies integrated with electronic healthcare records to improve patient clinical outcomes and their service experience. Website: www.genesiscare.com.au